{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T21:44:47Z","timestamp":1757454287554,"version":"3.41.2"},"reference-count":9,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2018,5,11]],"date-time":"2018-05-11T00:00:00Z","timestamp":1525996800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pediatric Blood &amp; Cancer"],"published-print":{"date-parts":[[2018,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Introduction<\/jats:title><jats:p>Bevacizumab\u2010based therapy has been demonstrated to be effective in the treatment of refractory or recurrent pediatric low\u2010grade glioma (LGG); however its efficacy as a single agent is less understood.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We report our experience with single\u2010agent bevacizumab for the treatment of recurrent or refractory LGG treated with either standard 2\u00a0week dosing (10\u00a0mg\/kg\/dose every 2\u00a0weeks) or with a standard 2\u00a0week dosing followed by an increased interval dosing (10\u00a0mg\/kg\/dose every 4\u00a0weeks).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>From 2012 to 2017, 15 patients (five males and 10 females) with recurrent\/refractory LGG (nine suprasellar, three thalamic, two brainstem, and one intramedullary spinal cord) were treated with a total of 156 doses of bevacizumab (115 every 2\u00a0week dosing, 41 every 4\u00a0week dosing, median 10 doses). Patients were refractory to a median of one nonsurgical therapy (range 0\u20133) prior to treatment with bevacizumab. Twelve of 15 demonstrated radiographic response (three complete, nine partial, and three stable disease). Significant clinical responses including improved visual fields (four), cranial neuropathy (three3), strength (seven), and gait (two) were observed. Bevacizumab was discontinued in 12 patients (resolution, one; disease stability, seven; progression, two; toxicity, one; and other, one) and three patients continue to receive monthly bevacizumab. Eleven patients eventually had radiographic progression (median 5 months, range 0.5\u201331) without clinical progression, and four of five receiving bevacizumab rechallenge had lpartial response.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Single\u2010agent bevacizumab is efficacious in the management of recurrent or refractory pediatric LGG with radiographic and clinical responses similar to those reported for bevacizumab\u2010based therapies.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pbc.27234","type":"journal-article","created":{"date-parts":[[2018,5,11]],"date-time":"2018-05-11T12:34:40Z","timestamp":1526042080000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Single\u2010agent bevacizumab in the treatment of recurrent or refractory pediatric low\u2010grade glioma: A single institutional experience"],"prefix":"10.1002","volume":"65","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1136-8543","authenticated-orcid":false,"given":"Hamza S.","family":"Gorsi","sequence":"first","affiliation":[{"name":"Department of Neurosciences University of California San Diego  La Jolla California"},{"name":"Rady Children's Hospital  San Diego California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paritosh C.","family":"Khanna","sequence":"additional","affiliation":[{"name":"Rady Children's Hospital  San Diego California"},{"name":"Department of Radiology University of California San Diego  La Jolla California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Tumblin","sequence":"additional","affiliation":[{"name":"Rady Children's Hospital  San Diego California"},{"name":"Department of Pediatrics Division of Hematology Oncology University of California San Diego  La Jolla California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lanipua","family":"Yeh\u2010Nayre","sequence":"additional","affiliation":[{"name":"Rady Children's Hospital  San Diego California"},{"name":"Department of Pediatrics Division of Hematology Oncology University of California San Diego  La Jolla California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehrzad","family":"Milburn","sequence":"additional","affiliation":[{"name":"Rady Children's Hospital  San Diego California"},{"name":"Department of Pediatrics Division of Hematology Oncology University of California San Diego  La Jolla California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer D.","family":"Elster","sequence":"additional","affiliation":[{"name":"Rady Children's Hospital  San Diego California"},{"name":"Department of Pediatrics Division of Hematology Oncology University of California San Diego  La Jolla California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John R.","family":"Crawford","sequence":"additional","affiliation":[{"name":"Department of Neurosciences University of California San Diego  La Jolla California"},{"name":"Rady Children's Hospital  San Diego California"},{"name":"Department of Pediatrics Division of Hematology Oncology University of California San Diego  La Jolla California"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2018,5,11]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.73.0242"},{"key":"e_1_2_9_3_1","first-page":"1257","article-title":"A multivariate analysis of factors determining tumor progression in childhood low\u2010grade glioma: a population based cohort study (CCLG CNS9702)","volume":"12","author":"Stokland T","year":"2010","journal-title":"Neuro Oncol"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.36.6054"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.34.5843"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22961"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/not154"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.24297"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1097\/MPH.0000000000000371"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.4161\/cbt.8.1.7237"}],"container-title":["Pediatric Blood &amp; Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpbc.27234","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pbc.27234","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,17]],"date-time":"2023-09-17T23:38:36Z","timestamp":1694993916000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pbc.27234"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,11]]},"references-count":9,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["10.1002\/pbc.27234"],"URL":"https:\/\/doi.org\/10.1002\/pbc.27234","archive":["Portico"],"relation":{},"ISSN":["1545-5009","1545-5017"],"issn-type":[{"type":"print","value":"1545-5009"},{"type":"electronic","value":"1545-5017"}],"subject":[],"published":{"date-parts":[[2018,5,11]]},"assertion":[{"value":"2018-01-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-04-16","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-05-11","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e27234"}}